Dr. Rasty brings 25+ years of experience in R&D, strategy, commercial, BD&L, and corporate leadership as the company advances novel, best-in-class medicines to treat CNS disorders

Rasty博士在研发、战略、商业、BD＆L和企业领导方面拥有25年以上的经验，因为该公司正在开发治疗中枢神经系统疾病的新型一流药物

BOSTON, April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.

波士顿，2024年4月17日/PRNewswire/--Sensorium Therapeutics（Sensorium），一家开发新型一流药物治疗多种中枢神经系统疾病的生物技术公司，今天宣布任命Sam Rasty博士为首席商务官。

'Sam's expertise will fuel our business development and commercial strategies as we continue to progress our lead programs towards the clinic,' said Alexandra Glucksmann, Ph.D., Chief Executive Officer of Sensorium. 'Having shepherded product development from discovery to commercialization across pharma and biotech companies of all sizes, he brings deep understanding of the drivers of market dynamics, business development, partnership, and other core activities as we prepare to become a clinical-stage company in early 2025.'.

Sensorium首席执行官AlexandraGlucksmann博士说，随着我们继续推进领先项目，Sam的专业知识将推动我们的业务发展和商业战略他指导了各种规模的制药和生物技术公司从发现到商业化的产品开发，在我们准备在2025年初成为临床阶段公司时，他对市场动态，业务发展，合作伙伴关系和其他核心活动的驱动因素有了深刻的理解。”。

Dr. Rasty was most recently Chief Executive Officer of Sequence Bio, a genomics and precision medicine company in Canada, President and Chief Executive Officer of PlateletBio, a pioneering cell therapy biotechnology company in the Boston area, and Board Director of Oxford Biomedica, a UK-based gene therapy company.

Rasty博士最近担任加拿大基因组学和精准医学公司Sequence Bio的首席执行官，波士顿地区开创性细胞治疗生物技术公司PlateletBio的总裁兼首席执行官，以及英国基因治疗公司Oxford Biomedica的董事会董事。

Previously, he served as Chief Operating Officer at Homology Medicines, a genetic medicines company that he helped launch in early 2016 and transform into a fully integrated public gene therapy and gene editing company. His earlier career spanned several leadership roles at Shire plc, Endo Pharmaceuticals, and GlaxoSmithKline in various capacities including R&D, new product planning, commercial strategy, marketing and business development.

此前，他曾担任Homology Medicines的首席运营官，Homology Medicines是一家基因药物公司，他于2016年初帮助成立，并转型为一家完全整合的公共基因治疗和基因编辑公司。他早期的职业生涯曾在Shire plc、Endo Pharmaceuticals和葛兰素史克担任过多个领导职务，包括研发、新产品规划、商业战略、营销和业务开发。

Dr. Rasty earned a Ph.D. in Biochemistry from Louisiana State University, completed a postdoctoral fellowship in Molecular Genetics at the University of Pittsburgh School of Medicine, and received an MBA from Villanova University..

拉斯蒂博士在路易斯安那州立大学获得了生物化学博士学位，在匹兹堡大学医学院完成了分子遗传学博士后研究，并获得了维拉诺瓦大学的MBA学位。。

'Sensorium's novel and de-risked drug discovery and development approach has incredible potential to bring forward best-in-class, novel therapies for CNS diseases that offer a significantly better efficacy and safety profile than current treatments,' said Dr. Rasty. 'I am eager to work alongside this dynamic team as we advance the company's differentiated programs toward the clinic.'.

拉斯蒂博士说：“Sensorium的新型且无风险的药物发现和开发方法具有惊人的潜力，可以为中枢神经系统疾病带来同类最佳的新型疗法，其疗效和安全性明显优于目前的疗法。”我渴望与这个充满活力的团队合作，推动公司的差异化项目走向诊所。”。

About Sensorium Therapeutics

关于感觉疗法

Sensorium Therapeutics is a biotechnology company leveraging chemistry, neuroscience, and machine learning to develop novel, best-in-class medicines for neuropsychiatric and neurological diseases. Our lead program, SENS-01, is a highly selective, fast-acting anxiolytic drug without sedative properties that is being developed to treat anxiety disorders.

Sensorium Therapeutics是一家利用化学，神经科学和机器学习开发新型，一流的神经精神和神经疾病药物的生物技术公司。我们的主要项目SENS-01是一种高选择性，速效抗焦虑药物，没有镇静特性，正在开发用于治疗焦虑症。

SENS-01 is significantly differentiated from current standard of care and is currently in mid-stage IND-enabling studies, expected to enter the clinic in early 2025..

SENS-01与当前的护理标准有很大区别，目前正在进行中期IND研究，预计将于2025年初进入诊所。。

Sensorium's Biodynamic Discovery Platform™ identifies and enhances natural molecules with a long history of human efficacy to develop proprietary, novel chemical entities that can translate into more effective modern medicines. Founded by world-class researchers, clinicians, and drug developers, the company completed a $30M Series A financing in late 2022 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others.

Sensorium的Biodynamic Discovery Platform™识别并增强具有悠久人类功效历史的天然分子，以开发专有的新型化学实体，从而转化为更有效的现代药物。该公司由世界一流的研究人员、临床医生和药物开发人员创立，于2022年末完成了由SantéVentures牵头的3000万美元a系列融资，其中包括Route 66 Ventures、CU Healthcare Innovation Fund等机构的参与。

Visit www.sensorium.bio to learn more..

访问www.sensorium.bio了解更多信息。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/sensorium-therapeutics-appoints-sam-rasty-as-chief-business-officer-302118457.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/sensorium-therapeutics-appoints-sam-rasty-as-chief-business-officer-302118457.html

SOURCE Sensorium Therapeutics

源感觉疗法